A pharmacokinetic study: ranibizumab, aflibercept and the effect of vitrectomy

Trial Profile

A pharmacokinetic study: ranibizumab, aflibercept and the effect of vitrectomy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Feb 2016

At a glance

  • Drugs Aflibercept (Primary) ; Ranibizumab (Primary)
  • Indications Age-related macular degeneration
  • Focus Pharmacokinetics
  • Acronyms VITCLEAR
  • Most Recent Events

    • 22 Jan 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 14 Aug 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
    • 20 Sep 2014 The comparator as aflibercept has been added to this trial, also title, endpoints are changed as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top